ZNTL - רווח תפעולי EBITDA Zentalis

סמל מסחרי של Zentalis (ZNTL)

Zentalis Pharmaceuticals (ZNTL) is developing the innovative azazenisertib to combat resistant tumors. Flawless thermologistics of the drugs guarantee therapy effectiveness, as confirmed by historical data on the GURU.Markets chart: the base EBITDA level shows that the latest mark is 0.00. The issuer's future success is based on clinical test results, while the current cash reserve remains sufficient.

Zentalis Pharmaceuticals (ZNTL) - רווח תפעולי EBITDA מ-23.11.2025 עד 16.11.2026

פילוחי נתונים אנליטיים מרוכזים עבור Zentalis Pharmaceuticals Inc (ZNTL)

- ציטוטים נוכחיים ותחזית שווי ממוצעת:
הערכת שווי פונדמנטלית של החברה:Zentalis Pharmaceuticals, ZNTL
מוצר המיוצר על ידי Zentalis Pharmaceuticals, Inc.

This indicator tracks daily net operating cash flow, allowing investors to promptly identify a critical reduction in resources for business development. When analyzing the EBITDA_Co trend, it should be noted that for Zentalis Pharmaceuticals (ZNTL), a lack of pricing power due to the clinical trial stage makes this metric a key marker of survival until regulatory certification of the drugs.